Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Martin Safanda"'
Autor:
Magda Barinova, Jana Skrickova, P. Opálka, Miloš Pešek, M. Černovská, Martin Safanda, Karolina Hurdalkova, Helena Coupkova, Martin Svaton, Daniel Krejci, Milada Zemanova, Monika Bratová, Michal Hrnčiarik, Daniel Dolezal, J. Krejčí, Petra Zemanova, Leona Koubková, Juraj Kultan, Ondrej Fischer
Publikováno v:
Anticancer Research. 41:2597-2603
Background/aim Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab are regimens used in combination with checkpoint inhibitors in non-squamous non-small cell lung cancer (NSCLC) treatment. We conducted a real-world study to compare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::057bcac6de29fe9f3a3ce1185eafb469
https://doi.org/10.21873/anticanres.15039
https://doi.org/10.21873/anticanres.15039
Autor:
Martin Svaton, Michal Hrnčiarik, Leona Koubková, Jana Skrickova, Monika Bratová, Daniel Dolezal, Jana Krejčí, Libor Havel, Martin Safanda, Helena Čoupková, Magda Barinova, Marketa Cernovska, Juraj Kultan, Kristián Brat, Ondrej Fischer, Tana Tuzova, Milada Zemanova, Karolina Hurdalkova, Miloš Pešek
Publikováno v:
Lung cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4c505604a7e449adfb38275957c2e3e
https://doi.org/10.1183/13993003.congress-2021.pa2306
https://doi.org/10.1183/13993003.congress-2021.pa2306
Autor:
Katja Björklöf, Daniela Niepel, Richard Greil, Antoaneta Tomova, Miriam Porubska, Martin Safanda, Andreas L. Petzer, Christine Jaeger, Zoltán Bajory, Dmitry Kalinin, Ferdinand Haslbauer
Publikováno v:
Supportive Care in Cancer
Purpose In the integrated analysis of phase III head-to-head trials in patients with advanced solid tumors, denosumab demonstrated superiority over zoledronic acid in preventing skeletal-related events (SREs). Regular and continued drug use (persiste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf434574f947a08de44f66530db6fd49
https://doi.org/10.1007/s00520-019-04988-7
https://doi.org/10.1007/s00520-019-04988-7
Publikováno v:
In Vivo. 31:303-306
Febrile neutropenia (FN) is a common and potentially fatal complication of anticancer treatment, particularly in patients receiving myelosuppressive chemotherapy. It has been shown that prophylaxis with granulocyte colony-stimulating factor (G-CSF),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c03d6bc402a2a4c6f6b77d4ac193206
https://doi.org/10.21873/invivo.11059
https://doi.org/10.21873/invivo.11059
Autor:
Alina Macovei, Lidia Popławska, Martin Safanda, Doru Ghizdavescu, Jana Benkovicova, Radosław Mądry, Tibor Csőszi, Christine Jaeger, Iveta Frkanova, Georgi Mihaylov, Ferdinand Haslbauer, Daniela Niepel, Christine Staudigl
Publikováno v:
Wiener Klinische Wochenschrift
Summary Objective To describe the incidence of febrile neutropenia (FN) and use of pegfilgrastim in cancer patients with high overall risk of FN and to investigate the relationship between granulocyte-colony stimulating factor (G-CSF) guideline adher
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::491bed00a92df9e86a3f8a9ca447b203
https://doi.org/10.1007/s00508-015-0917-1
https://doi.org/10.1007/s00508-015-0917-1
Publikováno v:
Anticancer research. 36(9)
Monoclonal antibodies binding the epidermal growth factor receptor (EGFR), such as cetuximab or panitumumab, are widely used targeted therapeutics for the treatment of patients with colorectal cancer. The clinical significance of these drugs has so f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9240be07cae602a6f1a0a4eff9d16464
https://pubmed.ncbi.nlm.nih.gov/27630277
https://pubmed.ncbi.nlm.nih.gov/27630277
Autor:
Radek, Kucera, Ondrej, Topolcan, Ondrej, Fiala, Judita, Kinkorova, Vladislav, Treska, Ilona, Zedníková, David, Slouka, Vaclav, Simanek, Martin, Safanda, Vaclav, Babuska
Publikováno v:
Anticancer research. 36(2)
The aim of the study was to assess the degree to which tissue polypeptide antigen (TPA) and tissue polypeptide-specific antigen (TPS), as well as carcinoembryonic antigen (CEA), can assist in the detection of distant metastases.We assessed 157 patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::936af7ef949edaf6f1ce8a27a8fec2fb
https://pubmed.ncbi.nlm.nih.gov/26851038
https://pubmed.ncbi.nlm.nih.gov/26851038
Autor:
Radek, Kucera, David, Smid, Ondrej, Topolcan, Marie, Karlikova, Ondrej, Fiala, David, Slouka, Tomas, Skalicky, Vladislav, Treska, Vlastimil, Kulda, Vaclav, Simanek, Martin, Safanda, Martin, Pesta
Publikováno v:
Anticancer research. 36(4)
The first aim of this study was to search for new biomarkers to be used in gastric cancer diagnostics. The second aim was to verify the findings presented in literature on a sample of the local population and investigate the risk of gastric cancer in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b1384c00378661b848212d6376b0a3bc
https://pubmed.ncbi.nlm.nih.gov/27069188
https://pubmed.ncbi.nlm.nih.gov/27069188
Autor:
Filip, Janku, Olga, Pribylova, Martina, Zimovjanova, Gabriela, Pazdrova, Martin, Safanda, Milad, Zemanova, Lubos, Petruzelka
Publikováno v:
Bulletin du cancer. 91(10)
Background. - Trastuzumab is known as an active agent in HER2/neu overexpressing advanced breast cancer. In the prospective study we investigated efficacy, safety and toxicity of trastuzumab and paclitaxel in advanced breast cancer progressing on pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2f7c9c9339d3505c8a61c31bbf699252
https://pubmed.ncbi.nlm.nih.gov/15582895
https://pubmed.ncbi.nlm.nih.gov/15582895
Autor:
Hana Honova, P. Mares, J. Dvorak, V. Tomancova, Milada Zemanova, Martin Safanda, Lubos Petruzelka
Publikováno v:
Lung Cancer. 49:S377
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7958cc3491f684f4c14e6d9ad78df4bd
https://doi.org/10.1016/s0169-5002(05)81471-0
https://doi.org/10.1016/s0169-5002(05)81471-0